Rising Incidence of Chronic Diseases Fuels Demand for Radiofrequency Ablation Devices, says Market.us

This market is primarily driven by the increasing prevalence of cardiovascular and chronic diseases, as well as a preference for minimally invasive surgery. According to the Centers for Disease Control and Prevention (CDC), 17.9 million people will experience Atrial Fibrillation in Europe by 2060 and 12 million Americans by 2050.

The growth is anticipated to be driven by an aging population and rising life expectancies. Geriatrics are especially vulnerable to chronic illnesses, creating a demand for radiofrequency ablation (RF ablation).

According to Market.us, “The Radio Frequency Ablation Devices Market is projected to reach a valuation of USD 11.07 Billion by 2032 at a CAGR of 11%, from USD 3.9 Billion in 2022.” 

Asia Pacific is expected to experience the fastest compound annual growth rate during the forecast period. Multi-needle electrodes, which offer accuracy, portability, and cost-efficiency, will have a major impact on this region’s market. 

Furthermore, rising disposable income, improved healthcare infrastructure, and rapid economic development in emerging countries such as China and India also play a role.

Anurag Sharma, a senior research analyst at Market.us, said, “RFA of Cardiac Arrhythmia has opened new possibilities in terms of procedural safety. No longer do patients require fluoroscopy to treat arrhythmia. RFA devices now enable both ICE imaging and EAM techniques to treat it more effectively. It’s expected that demand for this service will continue to grow at an exponential rate in the future.”

Market growth will be spurred on by an increasing prevalence of osteoporosis and arthritis, as well as improved healthcare infrastructure. In 2015 alone, 15,000,000 Americans experienced severe arthritis-related joint pain. By 2040, an estimated 78 million (26%) Americans will have been diagnosed with arthritis.

One of the primary drivers of global market growth is an increase in cardiovascular diseases and cancers (Lung Cancers, Kidney Cancers, Hepatocellular Cancer, Pancreatic Cancer, Bile Duct Cancer etc.). 

Cardiac ablation has seen steady growth over the years with an annual compounded growth rate (CAGR) of 12.78% and total revenue reaching USD 996.173 Mn in 2018.

The market for cancer and CVD drugs is projected to experience rapid growth between 2020-2030, driven by an increasing incidence of these illnesses. From 2020-2030, this market is anticipated to expand at a compound annual growth rate (CAGR) of 5.017%.

Geriatrics are more vulnerable to chronic illnesses, which has driven the market’s expansion. According to the World Health Organization (WHO), there will be 2 Bn people aged 60 or older by 2050 – up from 900 Mn today.

Global geriatric population growth, as well as an increasing prevalence of metastatic bone diseases such as osteoid osteomas, supraventricular Tachycardias and ventricular arrhythmias, renal sympathetic denervation, are all driving radiofrequency ablation technologies forward. 

Hypertension, varicose vein treatment, Obstructive Sleep Apnea treatments using balloon Radiofrequency Ablation or balloon-based radiofrequency Ablation techniques, uterine fibroids also benefit from radiofrequency back ablation success rates as well as catheter-based radiofrequency catheter ablation through CT scans are driving this technology forward.

The market can be divided into three segments based on product: disposable, capital, and reusable. Disposable equipment held the largest market share in 2018 and it’s predicted to grow at the fastest rate over the forecast period. 

Disposable radiofrequency ablation market growth is being spurred by advances in technology that create large areas of coagulative necrosis with reduced risks of complications.

Market growth will be driven primarily by product launches during the forecast period. Medtronic released the OsteoCool(r) RF Ablation system for Canada in April 2017, which can be used to detect bone metastases. As the only RF Ablation System with dual probe capabilities, this offers a personalized, flexible, and predictable solution.

The market can be divided by application into surgical oncology and cardiology, cardiac rhythm management (pain management), gynecology, and cosmetology; with surgical oncology holding the largest share in 2018.

Radiofrequency ablation can be used as part of cancer treatments to boost survival rates for those at high risk with unresectable or refractory tumors. Patients requiring multiple surgeries that cannot be addressed openly can utilize RF ablation to minimize side effects and speed up recovery times for these treatments as well.

Due to an increase in Atrial Fibrillation (AF) risk, cardiology and cardiac rhythm management segments are expected to experience the fastest compound annual growth rate over the forecast period. 

According to the Department of Health’s National Service Framework for Coronary Heart Disease, AF is the most prevalent arrhythmia. Catheter ablation is anticipated to become the most frequently performed electrophysiological procedure over the upcoming years, fuelling market expansion.

The Radiofrequency Ablation Devices market key players include:

• Sutter Medizintechnik Gmbh
• AtriCure
• C. R. Bard
• Inomed Medizintechnik GmbH
• Epimed International
• Arthrex